Alexander Lifke
Principal Scientist @Boehringer Ingelheim
Signup · Get unlimited contacts
WORK HISTORY
Principal Scientist @Boehringer Ingelheim
Ingelheim am Rhein, DE
New Target identification and characterization in Oncology discovery team• Preclinical evaluation of therapeutic candidates • Identification and evaluation of disease pathway targets and innovative therapeutic approaches• Ensure the progress through the product pipeline to advance R&D business objectives• Design and supervise exploratory research activities: disease characterization, target selection/engagement/validation, and drug candidate characterization/identification
EDUCATION
Johannes Gutenberg University Mainz
PhD, Tumor Immunology
Novosibirsk State University (NSU)
Master’s Degree, Molecularbiology
SKILLS
ABOUT ALEXANDER LIFKE
More than 15 years experience in tumor immunology,cell biology, molecular biology and virology• Research experience in academia and pharmaceutical industry• In depth knowledge for the preclinical evaluation of novel small- and large molecule drug candidates, particularly antibodies as anti-tumor agents, • Recent focus is the identification, characterization and validation of novel targets for ant-tumor therapies• Evaluation of cancer immune therapeutic approaches such as- redirection of pathogen specific T-cells against cancer (initiation and development of the concept and design of proof of concept experiments)- in vivo efficacy of T-cell-activating-bispecific (TCB) molecules (validation of humanized mice model for the functional assessment of TCB)- characterization of immune responses in vitro / in vivo after treatment with immune modulators - evaluation of combinatorial anti cancer immune therapy• Developing new methods and experimental models with emphasis on more predictive preclinical in vivo models using immune deficient mice with a reconstituted and fully functional human immune system• Principal inventor of the technology for the generation of fully human antibodies in the humanized mouse model• Principal inventor of the technology for the generation of Immunoconjugates for specific induction of T cell cytotoxicity against a target cell• Principal inventor of the technology for obtaining Fab fragments from single cell antibody producing cells by multiplexed PCR in combination with TaqMan probes
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.